Eli Lilly and Company

Quick Take

In November 2025, Lilly signed a "Most Favored Nation" drug pricing agreement with the Trump administration to cut Zepbound and other GLP-1 drug prices for some Medicare and Medicaid beneficiaries — part of a broader administration package that also brought tariff relief and FDA priority vouchers to participating drugmakers. By April 2026, CEO David Ricks publicly broke from that posture, telling CNBC that Lilly opposes any effort to codify the deal into permanent law and will use "all the tools" available to fight it. Lilly's federal PAC giving to candidates in 2024 leaned modestly Republican at approximately 60 percent to 40 percent, while broader organizational giving (including individual contributions, party committees, and soft money) ran closer to a 53/47 Republican-Democrat split — making Lilly's overall federal political activity more balanced than industry peers but with a clear Republican preference at the candidate level. The company has continued publicly committing to clinical trial diversity and inclusive workplace programs in 2025-2026 even as several US health insurers and pharmaceutical peers scaled back DEI language; on the same day this profile was researched (May 6, 2026), the company announced an additional $4.5 billion Indiana manufacturing investment that President Trump publicly amplified on Truth Social.

Public Political Activity

According to OpenSecrets data, Eli Lilly-affiliated political contributions in the 2024 election cycle totaled approximately $1.86 million across PAC and individual giving, with federal lobbying expenditures of approximately $6.72 million.[1] Lilly does not maintain a federal contractor restriction posture comparable to ExxonMobil; the company's corporate-treasury and PAC-funded political activity is fully disclosed under federal law.

Lilly's overall political activity has run more balanced than many industry peers, though candidate-level PAC giving continues to lean modestly Republican. According to OpenSecrets PAC data, the Eli Lilly & Co PAC gave approximately $495,000 directly to federal candidates in the 2023-2024 cycle, with the candidate-level split running approximately 60 percent Republican to 40 percent Democrat.[2] When measured across broader organizational giving — including individual contributions from employees, party committee giving, and soft money — the split moves closer to 53 percent Republican to 47 percent Democrat per OpenSecrets aggregated totals. The two breakdowns together indicate that Lilly's federal candidate giving has a clear Republican preference at the PAC level, but the company's rank-and-file employee giving and party-level activity bring the broader picture closer to balance. BioSpace reporting on 2024 cycle pharmaceutical industry giving placed Lilly's individual employee giving at approximately $480,000 to Republicans and $317,000 to Democrats during the 2023-2024 reporting period — slightly Republican-leaning at the rank-and-file level.[3]

The company publishes detailed political contribution reports on its Public Policy Engagement page, going beyond minimum federal disclosure requirements with semi-annual mid-year reports.[4] Lilly maintains active membership in pharmaceutical trade associations including PhRMA (the industry's primary lobbying voice), which engages on policy issues affecting drug pricing, intellectual property, and FDA regulation.

Public Positions and Statements

Lilly's public political posture in 2025-2026 has been notably mixed, with the company taking actions and positions that read as both right-aligned and left-aligned depending on the policy area.

Drug pricing — November 2025 Trump deal. On November 6, 2025, Lilly CEO David Ricks appeared in the Oval Office alongside President Trump to announce a Most Favored Nation (MFN) drug pricing agreement.[5] Under the deal, Lilly agreed to sell Zepbound and the diabetes drug Mounjaro at $245 per month to some Medicare beneficiaries through a pilot program and to state Medicaid programs that opt in — a substantial reduction from list prices around $1,080 — and to make starter doses of future oral GLP-1 medications available at $149 per month.[6] As part of the broader administration package extended to multiple drug manufacturers, Lilly received three-year relief from potential Section 232 national-security tariffs on pharmaceutical imports, and the FDA awarded "national priority" voucher access for specific Lilly drugs including the oral GLP-1 candidate orforglipron.[7] The agreement was framed by the Trump administration as a major win for American consumers and was covered by financial press as one of the most prominent corporate cooperations with the second Trump administration's drug pricing agenda, alongside parallel deals with Pfizer, AstraZeneca, EMD Serono, and Novo Nordisk.

Drug pricing — April 2026 reversal. Five months later, on April 1, 2026, CEO Ricks told CNBC that Lilly opposes White House efforts to codify the MFN pricing approach into permanent law.[8] "We will use all the tools we have to combat bad policy, and we think it would be bad policy," Ricks said. The reversal places Lilly in the unusual position of having operationally cooperated with the administration while opposing the legislative entrenchment of that cooperation — a posture that protects the company's flexibility to renegotiate or exit the arrangement under a future administration.

Diversity and inclusion. Lilly has continued to publicly affirm its commitment to clinical trial diversity and workforce inclusion programs through 2025 and into 2026, even as several pharmaceutical peers and major US health insurers scaled back DEI language. According to Fierce Biotech reporting in February 2025, Lilly was one of four major drugmakers (alongside Bristol Myers Squibb, Sanofi, and Genentech) that explicitly reaffirmed commitments to diverse clinical trials following Trump's anti-DEI executive actions.[9] At the same time, Washington Post analysis noted that Lilly's 2024 annual shareholder letter made zero references to "DEI" — down from 48 references the prior year — suggesting a quieter rebrand of the same programs rather than their elimination.[10]

US manufacturing expansion. Lilly announced approximately $27 billion in new US manufacturing investment commitments in February 2025, covering four new domestic manufacturing sites focused on active pharmaceutical ingredients and finished injectables. Combined with approximately $23 billion in investments made since 2020, Lilly's total US manufacturing capital commitments now exceed $50 billion. The company's domestic production posture has aligned closely with the second Trump administration's industrial policy preferences regardless of its individual political donations. On May 6, 2026, the company announced an additional $4.5 billion investment in its home state of Indiana, including a new genetic-disease facility and expanded production for the oral weight-loss pill Foundayo, recently approved by the FDA.[11] President Trump publicly amplified the announcement on Truth Social. The cumulative $21 billion in Indiana investments since 2020 — a subset of the $50 billion in total US capital commitments — reflects a deep concentration of domestic-production capacity in the company's home state.

Products and Customer Base

Lilly's product portfolio spans diabetes (Mounjaro, Trulicity, Humalog and other insulins), obesity (Zepbound, Foundayo), oncology (Verzenio, Jaypirca, Retevmo), immunology (Olumiant, Taltz), neuroscience (Emgality, Cymbalta historically), and Alzheimer's disease (Kisunla). The GLP-1 franchise of Mounjaro and Zepbound, both based on the molecule tirzepatide, has driven the bulk of the company's revenue growth since 2023 and has positioned Lilly as the dominant US player in the obesity treatment market alongside competitor Novo Nordisk.

Customers include patients with insurance coverage through Medicare, Medicaid, and commercial plans, as well as cash-pay patients accessing medications through the LillyDirect direct-to-consumer pharmacy channel, which the company launched in 2024. Lilly also markets internationally through subsidiaries operating under the Lilly name in over 110 countries.

Founding and Ownership

Eli Lilly and Company was founded in 1876 in Indianapolis, Indiana, by Colonel Eli Lilly, a Civil War veteran and pharmaceutical chemist. The company has remained continuously based in Indianapolis for nearly 150 years. It was an early pioneer in insulin manufacturing in the 1920s, in partnership with the Canadian researchers who first isolated the hormone, and built much of its 20th-century reputation on insulin, antibiotics, and central-nervous-system drugs including Prozac. The Lilly Endowment Inc., established by family members in 1937, remains one of the largest private foundations in the United States, though the foundation operates independently of the company.

The company is now publicly held with a broad institutional shareholder base; the largest holders include Vanguard, BlackRock, and State Street, consistent with broader institutional ownership patterns of large-cap US pharmaceuticals. David A. Ricks has served as Chairman and CEO since 2017.

Where to Find Them

Eli Lilly corporate and investor information is available at the corporate website, and patient-facing information about specific medications and the LillyDirect cash-pay pharmacy channel is available at the LillyDirect website. Lilly does not operate retail locations directly; its medicines are dispensed through pharmacy partners, hospital systems, and the LillyDirect channel for select obesity treatments. The company's historical headquarters complex in downtown Indianapolis remains operational alongside expanding manufacturing campuses across Indiana including the new Lilly Lebanon Advanced Therapies facility.

Footnotes

[1] OpenSecrets.org, "Eli Lilly & Co Summary," accessed May 6, 2026. https://www.opensecrets.org/orgs/eli-lilly-co/summary?id=d000000166

[2] OpenSecrets.org, "Eli Lilly & Co PAC Candidate Recipients (2024 cycle)," accessed May 6, 2026. https://www.opensecrets.org/political-action-committees-pacs/eli-lilly-co/C00082792/candidate-recipients/2024

[3] Tyler Patchen, BioSpace, "As Election Nears, Pharma Hedges Campaign Contribution Bets," August 7, 2024. https://www.biospace.com/policy/as-election-nears-pharma-hedges-campaign-contribution-bets

[4] Eli Lilly and Company, "Public Policy Engagement & Political Participation," accessed May 6, 2026. https://www.lilly.com/policies-reports/public-policy-political-participation

[5] Eli Lilly and Company (investor relations), "Lilly and U.S. government agree to expand access to obesity medicines to millions of Americans," November 6, 2025. https://investor.lilly.com/news-releases/news-release-details/lilly-and-us-government-agree-expand-access-obesity-medicines

[6] Ned Pagliarulo, BioPharma Dive, "Novo, Lilly cut deal with Trump to lower prices of obesity drugs," November 7, 2025. https://www.biopharmadive.com/news/lilly-novo-trump-obesity-drug-pricing-deal-zepbound-wegovy/804905/

[7] Nathaniel Weixel, The Hill, "Gallego demands answers on Eli Lilly's deal with Trump," November 18, 2025. https://thehill.com/policy/healthcare/5611047-sen-gallego-lilly-trump-deal/

[8] Annika Kim Constantino, CNBC, "Eli Lilly opposes push to pass Trump's drug pricing deals into law, CEO says," April 1, 2026. https://www.cnbc.com/2026/04/01/eli-lilly-opposes-trump-mfn-drug-pricing-law-ceo-ricks-says.html

[9] Nick Paul Taylor, Fierce Biotech, "As Trump targets DEI practices, 4 pharmas reaffirm commitment to diversifying clinical trials," February 28, 2025. https://www.fiercebiotech.com/cro/trump-targets-dei-4-pharmas-reaffirm-commitments-diversifying-clinical-trials

[10] Taylor Telford, The Washington Post, "DEI is getting a new name. Can it dump the political baggage?", May 5, 2024. https://www.washingtonpost.com/business/2024/05/05/dei-affirmative-action-rebrand-evolution/

[11] Ahmed Farhath, Stocktwits, "Lilly Invests An Additional $4.5B in Indiana - Why Does This Investment Matter Now?", May 6, 2026. https://stocktwits.com/news-articles/markets/equity/lilly-invests-an-additional-4-5-b-in-indiana-why-does-this-investment-matter-now/cZQzOTeReOW